


**PRODUCT: ORY-1001**

**ALTERNATE NAMES:** N1-((1R,2S)-2-phenylcyclopropyl)cyclohexane-1,4-diamine, dihydrochloride; RG-6016

**CATALOG NUMBER:** B1957-1, 5

**AMOUNT:** 1 mg, 5 mg

**STRUCTURE:**

**MOLECULAR FORMULA:** C<sub>15</sub>H<sub>24</sub>Cl<sub>2</sub>N<sub>2</sub>

**MOLECULAR WEIGHT:** 303.27

**CAS NUMBER:** 1431326-61-2

**APPEARANCE:** Crystalline solid

**SOLUBILITY:** DMSO (~7 mg/ml)

**PURITY:** ≥98% by HPLC

**STORAGE:** Store at -20 °C. Protect from air and light

**DESCRIPTION:** ORY-1001 is a potent and selective inhibitor of LSD1 (IC<sub>50</sub> < 20 nM). It targets acute myeloid leukemia (AML) stem cells and significantly reduces tumor cell load while increasing survival time in mouse models of AML. ORY-1001 is in clinical trials for cancer treatment.

**REFERENCES:** Maes, T., *et al.* (2015). *Epigenomics* **7**, 609-626.

**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

**RELATED PRODUCTS:**

A-366 (Cat. No. 2859-1, 5)

AMI-1 (Cat. No. 1943-5, 25)

Aza-2'-deoxycytidine (Cat. No. 1754-10, 50)

BAZ2-ICR (B1865)

BI-7273 (B1879)

BI-9564 (B1880)

BIX01294 (Cat. No. 1678-5, 25)

Bromodomain Inhibitor, (+)-JQ1 (Cat. No. 2070-1, 5)

BRD4770 (Cat. No. 9525-5, 25)

EZSolution™ (+)-JQ1 (Cat. No. 2091-1)

3-Deazaneplanocin (Cat. No. 2060-250, 1000)

2'-Deoxy-5-fluorocytidine (Cat. No. 2387-50, 250)

EPZ-015666 (Cat. No. 9510-1,5)

EPZ011989 (Cat. Np. B1221-5,25)

Lomeguatrib (Cat. No. 2224-5, 25)

Mivebresib (Cat. No. B1564-5,25)

Nanaomycin A (Cat. No. 2790-5, 25)

ORY-1001 (Cat. No. B1957-5,25)

RG108 (Cat. No. 1679-10, 30)

SGI-1027 (Cat. No. 2726-5, 25)

UNC0638 (Cat. No. 1933-1, 5)

UNC0642 (Cat. No. 2862-5, 25)

Zebularine (Cat. No. 2225-1,

**USAGE:** **FOR RESEARCH USE ONLY! Not to be used in humans**